I noted the diagram on page two re targeted delivery in the liver. The GalNac cargo binds to the Asialoglycoprotein receptor and as a result can increase its potency and delivery into the liver cell by 30-60 fold, to potentially correct the disease in question. That's very impressive. So not only is it able to improve the uptake of cargo over conventional CPPs, it's able to do so more efficiently directly into the cell type of interest, in this case, the liver cell. More importantly, why is it able to produce these results within that particular cell type?
Cheers,
Tony
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.005(0.43%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.17 | $1.16 | $13.69K | 11.81K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 962 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 2237 | 3 |
View Market Depth
| Last trade - 10.45am 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |